The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...

The recent success story of twice yearly shots of Lenacapavir preventing HIV in over 96 percent of at-risk people and the Gilead granting royalty-free voluntary licenses to six generic pharma globally ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...